Brokerage Focus: AMTD International to buy SinoFert (00297) with a bullish rating, optimistic about its development of biological + new fertilizers driving performance growth.
Jingwu Financial News | Anxin International Research and Development Point: Sinofert (00297) achieved a 4.7% growth in net income attributable to shareholders in the first half of the year, reaching 1.05 billion, exceeding expectations. Sinofert's revenue in the first half of 2024 reached 13.68 billion, a year-on-year increase of 4.2%, with a net income of 1.05 billion, a year-on-year increase of 4.7%. Influenced by fluctuations in raw material prices and the downward trend of agricultural product prices, the prices of the company's main products showed a V-shaped pattern, with a weak downward trend at the beginning of the year, gradually rebounding in April, and some product prices at the end of June were higher than the same period last year. The bank pointed out that the sales volume of various differentiated products of the company in the first half of the year totaled 132.
Sinofert Holdings Limited's (HKG:297) Business Is Trailing The Market But Its Shares Aren't
Stocks in Hong Kong Surged: Sinofert (00297) rose more than 4%, with shareholders' attributable net profit for the first half of the year reaching 1.051 billion yuan, a year-on-year increase of 4.68%.
Sinofert (00297) rose by over 4%, as of the deadline, it increased by 4.26%, to 0.98 Hong Kong dollars, with a turnover of 5.4137 million Hong Kong dollars.
Sinofert (00297) released its interim results with a shareholder net profit of 1.051 billion yuan, a year-on-year increase of 4.68%, firmly promoting the "biological+" global strategy transformation.
Sinofert (00297) announced its interim performance for the six months ending June 30, 2024, with a group revenue of ...
[HK Connect] Sinofert (00297) recorded a 4.68% year-on-year increase in half-year net profit to 1.051 billion RMB, with no dividend payment.
Jingu Financial News | sinofert (00297) announced that as of June 30, 2024, the shareholder's attributable surplus amounted to 1.051 billion yuan (RMB, the same below), a year-on-year increase of 4.68%, with basic earnings per share of 0.1496 yuan and no interim dividend. During the period, the turnover was 13.681 billion yuan, a year-on-year increase of 4.21%; gross profit amounted to 1.663 billion yuan, a year-on-year increase of 7.25%.
Sinofert: To Increase R&D Investment, Improve Product Quality >0297.HK
Sinofert: Higher Possibility of More Countries Cutting Interest Rates in 2H >0297.HK
Sinofert: No Interim Dividend Declared >0297.HK
Sinofert Holdings Reports Steady Growth Amid Challenges
Express News | Sinofert - Hy Profit Attributable RMB1,051 Mln, up 4.68% YoY
Express News | Sinofert Holdings H1 ROE 10.47%
Express News | Sinofert Holdings H1 Revenue RMB 13,681 Million
Express News | Sinofert Holdings H1 Basic EPS RMB 0.1496
Express News | Sinofert Holdings H1 Gross Profit RMB 1,663 Million
SINOFERT: INTERIM RESULTS ANNOUNCEMENT - FOR THE SIX MONTHS ENDED 30 JUNE 2024
HK stocks fluctuations | Sinofert (00297) rose more than 3%. Institutions point to biotechnology innovation business as its future development focus, which is expected to drive performance growth.
Sinofert (00297) rose more than 3%. As of press time, it rose 3.30% to HKD 0.94, with a turnover of 8.4748 million Hong Kong dollars.
Sinofert Holdings Schedules Key Financial Meeting
SinoFert (00297.HK) held a board of directors meeting on August 26th to discuss and approve its mid-term performance.
Sinofert (00297.HK) announced that the board of directors will hold a meeting on Monday, August 26, 2024, to discuss and approve the unaudited mid-term performance as of June 30, 2024 of the company and its subsidiaries, as well as to consider the distribution of interim dividends (if any).
SINOFERT: ANNOUNCEMENT - DATE OF BOARD MEETING
Anxin International is the first to give a "buy" rating to Sinofert (00297) with a target price of HKD 1.4.
Anxin International predicts that Sinofert (00297) will have a net income attributable to its parent of 840 million/920 million/1.01 billion in the fiscal years of 2024-2026.
No Data